知搜-全球专利检索

  1. 登录
  2. 注册

搜索结果

722 条记录 (耗时 0.045 秒)

    MUTANT BOTULINUM NEUROTOXIN SEROTYPE A POLYPEPTIDE AND USES THEREOF
    72.
    发明申请
    MUTANT BOTULINUM NEUROTOXIN SEROTYPE A POLYPEPTIDE AND USES THEREOF 失效
    突变型嗜碱性神经毒素SEROTYPE A POLYPEPTIDE及其用途

    公开(公告)号：US20100247560A1

    公开(公告)日：2010-09-30

    申请号：US12679936

    申请日：2008-09-25

    申请人： Lance L. Simpson ,  Mohammed Elias

    发明人： Lance L. Simpson ,  Mohammed Elias

    IPC分类号： A61K39/08 ,  C12P21/06 ,  C12N5/00 ,  C12N15/63 ,  C07K14/33 ,  C07K16/00 ,  C07H21/04

    CPC分类号： A61K39/08 ,  A61K2039/522 ,  A61K2039/55511 ,  C07K14/33 ,  Y02A50/469

    摘要： Modified polypeptides based on the botulinum neurotoxin A heavy chain containing the double mutation Trp-Tyr->Leu-Ser in the ganglioside binding motif Ser-X-Trp-Tyr do not bind polysialogangliosides and nerve endings. The polypeptides are useful in the preparation of nontoxic vaccines against the effects of C. botulinum infection. The modified polypeptides are also useful as vehicles for the transepithelial delivery of diagnostic and therapeutic entities, through formation of conjugates between the polypeptides and the diagnostic or therapeutic entities.

    摘要翻译： 基于肉毒杆菌神经毒素的修饰多肽在神经节苷脂结合基序Ser-X-Trp-Tyr中含有双突变Trp-Tyr-> Leu-Ser的重链不结合聚唾液酸神经节苷脂和神经末梢。 该多肽可用于制备针对肉毒杆菌感染作用的无毒性疫苗。 经修饰的多肽也可用作通过形成多肽和诊断或治疗实体之间的缀合物来诊断和治疗实体的跨上皮传递的载体。

    DIAGNOSIS AND TREATMENT OF CANCERS WITH MicroRNA LOCATED IN OR NEAR CANCER-ASSOCIATED CHROMOSOMAL FEATURES
    73.
    发明申请
    DIAGNOSIS AND TREATMENT OF CANCERS WITH MicroRNA LOCATED IN OR NEAR CANCER-ASSOCIATED CHROMOSOMAL FEATURES 审中-公开
    诊断和治疗位于或接近癌相关染色体特征的微小RNA

    公开(公告)号：US20100234241A1

    公开(公告)日：2010-09-16

    申请号：US12767279

    申请日：2010-04-26

    申请人： Carlo M. Croce ,  Chang-Gong Liu ,  George A. Calin ,  Cinzia Sevignani

    发明人： Carlo M. Croce ,  Chang-Gong Liu ,  George A. Calin ,  Cinzia Sevignani

    IPC分类号： C40B30/04 ,  C12Q1/68

    CPC分类号： C12N15/1135 ,  A61K31/7088 ,  A61K31/713 ,  A61K45/06 ,  C12N7/00 ,  C12N15/113 ,  C12N2310/11 ,  C12N2310/141 ,  C12N2310/31 ,  C12N2310/32 ,  C12N2310/33 ,  C12N2710/16143 ,  C12Q1/6886 ,  C12Q2600/106 ,  C12Q2600/158 ,  C12Q2600/178

    摘要： MicroRNA genes are highly associated with chromosomal features involved in the etiology of different cancers. The perturbations in the genomic structure or chromosomal architecture of a cell caused by these cancer-associated chromosomal features can affect the expression of the miR gene(s) located in close proximity to that chromosomal feature. Evaluation of miR gene expression can therefore be used to indicate the presence of a cancer-causing chromosomal lesion in a subject. As the change in miR gene expression level caused by a cancer-associated chromosomal feature may also contribute to cancerigenesis, a given cancer can be treated by restoring the level of miR gene expression to normal. microRNA expression profiling can be used to diagnose cancer and predict whether a particular cancer is associated with an adverse prognosis. The identification of specific mutations associated with genomic regions that harbor miR genes in CLL patients provides a means for diagnosing CLL and possibly other cancers.

    摘要翻译： MicroRNA基因与涉及不同癌症病因的染色体特征高度相关。 由这些与癌症相关的染色体特征引起的细胞的基因组结构或染色体结构的扰动可影响位于该染色体特征附近的miR基因的表达。 因此，miR基因表达的评估可用于指示受试者中存在致癌染色体损伤。 由于由癌相关的染色体特征引起的miR基因表达水平的变化也可能导致致癌作用，可以通过将miR基因表达水平恢复到正常来治疗给定的癌症。 microRNA表达谱可用于诊断癌症并预测特定癌症是否与不良预后相关。 与CLL患者中含有miR基因的基因组区域相关的特异性突变的鉴定提供了诊断CLL和可能的其他癌症的手段。

    COMPOSITIONS AND METHODS FOR CANCER DIAGNOSIS AND THERAPY
    75.
    发明申请
    COMPOSITIONS AND METHODS FOR CANCER DIAGNOSIS AND THERAPY 有权
    用于癌症诊断和治疗的组合物和方法

    公开(公告)号：US20100173319A1

    公开(公告)日：2010-07-08

    申请号：US12727778

    申请日：2010-03-19

    申请人： Carlo Croce ,  George Calin

    发明人： Carlo Croce ,  George Calin

    IPC分类号： C12Q1/68

    CPC分类号： A61K9/127 ,  A61K31/70 ,  A61K48/005 ,  C12N15/113 ,  C12N2310/141 ,  C12N2330/10 ,  C12Q1/6886 ,  C12Q2600/178

    摘要： The miR15 and miR16 micro RNA genes are located at 13q14 within a 30 kb region of loss characteristic of cells from certain cancers, such as cells from chronic lymphocytic leukemia or prostate cancer. Chronic lymphocytic leukemia or prostate cancer can be diagnosed by detecting a reduction in miR15 or miR16 gene copy number, by determining miR15 or miR16 gene mutational status, or by detecting a reduction in the RNA transcribed from these genes. The miR15 or miR16 gene products can inhibit the neoplastic or tumorigenic growth of cancers such as chronic lymphocytic leukemia or prostate cancer cells when administered to subjects suffering from these diseases.

    摘要翻译： miR15和miR16微RNA基因位于13q14位于来自某些癌症（例如来自慢性淋巴细胞白血病或前列腺癌的细胞）的细胞损失特征的30kb区域内。 通过测定miR15或miR16基因突变状态，或通过检测从这些基因转录的RNA的减少，可以通过检测miR15或miR16基因拷贝数的减少来诊断慢性淋巴细胞性白血病或前列腺癌。 当给予患有这些疾病的受试者时，miR15或miR16基因产物可以抑制癌症例如慢性淋巴细胞白血病或前列腺癌细胞的肿瘤或致瘤性生长。

    Recombinant rabies virus compositions
    77.
    发明授权
    Recombinant rabies virus compositions 有权
    重组狂犬病病毒组合物

    公开(公告)号：US07695724B2

    公开(公告)日：2010-04-13

    申请号：US11571842

    申请日：2005-07-12

    申请人： Bernhard Dietzschold ,  Marie Luise Faber ,  Matthias Schnell ,  Milosz Faber

    发明人： Bernhard Dietzschold ,  Marie Luise Faber ,  Matthias Schnell ,  Milosz Faber

    IPC分类号： A61K39/205 ,  C12N7/00 ,  C12N7/01 ,  C12N15/86

    CPC分类号： C12N7/00 ,  A61K35/13 ,  C07K14/005 ,  C12N2760/20121 ,  C12N2760/20122 ,  C12N2760/20161

    摘要： Recombinant rabies viruses in which the arginine residue of the glycoprotein (G) at amino acid position 333 is exchanged, renders these viruses nonpathogenic for immunocompetent mammals regardless of the route of infection. Some of these recombinant rabies viruses after several serial virus passages in newborn mice can become pathogenic for adult mice. The reversion to the pathogenic phenotype is associated with a thymidine to adenosine mutation (T→A) at position 639 of the G gene, which results in an asparagine to lysine exchange at position 194 of G. The codon at position 637-639 was changed by site directed mutagenesis to replace asparagine at position 194 by an amino acid that minimized the possibility for an Asn→Lys exchange at amino acid position 194 of G and prevents reversion to a pathogenic form of the virus.

    摘要翻译： 在氨基酸位置333处交换糖蛋白（G）的精氨酸残基的重组狂犬病毒使得这些病毒对于免疫活性的哺乳动物是非致病性的，而不管感染途径如何。 新生小鼠中几种连续病毒传代后的这些重组狂犬病病毒中的一些可能成为成年小鼠致病的。 对病原性表型的逆转与G基因位置639处的胸苷与腺苷突变（T→A）相关，导致在G位置194处天冬酰胺至赖氨酸交换。位置637-639的密码子被改变 通过位点定向诱变来替代位置194处的天门冬酰胺，其最小化在G的氨基酸位置194处的Asn→Lys交换的可能性，并防止逆转到病毒形式的病原体。

    Human chronic lymphocytic leukemia modeled in mouse by targeted TCL1 expression
    79.
    发明申请
    Human chronic lymphocytic leukemia modeled in mouse by targeted TCL1 expression 有权
    通过靶向TCL1表达在小鼠中建模的人慢性淋巴细胞白血病

    公开(公告)号：US20080256650A1

    公开(公告)日：2008-10-16

    申请号：US12080907

    申请日：2008-04-07

    申请人： Carlo M. Croce

    发明人： Carlo M. Croce

    IPC分类号： A01K67/027

    CPC分类号： C07K14/47 ,  A01K67/0275 ,  A01K2217/05 ,  A01K2227/105 ,  A01K2267/0331 ,  C12N15/8509

    摘要： Transgenic animals containing a nucleic acid sequence encoding TCL1 operably linked to transcriptional control sequences directing expression to B cells are described. Such transgenic animals provide a useful animal model system for human B cell chronic lymphocytic leukemia.

    摘要翻译： 描述了含有编码TCL1的核酸序列的转基因动物，其可操作地连接到将表达指导到B细胞的转录控制序列。 这样的转基因动物为人B细胞慢性淋巴细胞性白血病提供了有用的动物模型系统。

    Mimetics of CD4 that inhibit immune response
    80.
    发明授权
    Mimetics of CD4 that inhibit immune response 失效
    抑制免疫反应的CD4的模拟物

    公开(公告)号：US07345020B2

    公开(公告)日：2008-03-18

    申请号：US10841050

    申请日：2004-05-07

    申请人： Robert Korngold ,  Ziwei Huang

    发明人： Robert Korngold ,  Ziwei Huang

    IPC分类号： A61K38/08 ,  A61K38/12 ,  C07K4/00 ,  A61K38/00 ,  A61K38/04

    CPC分类号： C07K14/70514 ,  A61K31/395 ,  A61K38/00 ,  Y10S930/27

    摘要： The application concerns a method of identifying compounds that can be used to inhibit undesired human CD4+ T cell immune responses by identifying compounds that block the interaction of CD4 and MHC, class II, gene products and a method of treatment which comprises administering such an identified compound. The compounds that inhibit undesired human CD4+ T cell immune responses can be used to treat disease such as multiple sclerosis and to prevent graft rejection and graft versus host disease. More specifically, the application concerns compounds having molecular weights between about 1400 and 400 that mimic three portions of the human CD4 lymphocyte cell surface antigen. The portions are residues 29-35, the C—C′ loop of the D1 domain; residues 317-323, the C—C′ loop of the D4 domain; and residues 346-353, the CDR3 or FG ridge of the D4 domain of the CD4 molecule. Specific examples of such compounds include cyclic peptides and peptidomimetic.

    摘要翻译： 本申请涉及通过鉴定阻断CD4和MHC，II类基因产物的相互作用的化合物，鉴定可用于抑制不需要的人CD4 + T细胞免疫应答的化合物的方法， 包括施用这种鉴定的化合物。 抑制不需要的人CD4 + T细胞免疫应答的化合物可用于治疗疾病如多发性硬化，并防止移植排斥和移植物抗宿主病。 更具体地，本申请涉及模拟人CD4淋巴细胞表面抗原三部分的分子量在约1400和400之间的化合物。 这些部分是D1结构域的残基29-35，C-C'环; 残基317-323，D4结构域的C-C'环; 和残基346-353，CD4分子的D4结构域的CDR3或FG脊。 这些化合物的具体实例包括环肽和肽模拟物。